Finding Could Lead to Treatment to Prevent Infection Associated with Catheters and Medical Implants.
Scientists from the National Institutes of Health have discovered how catheter-related bacterial infection develops and disseminates to become a potentially life-threatening condition. The study, which included research on Staphylococcus epidermidis in mice implanted with catheters, could have important implications for understanding many types of bacterial biofilm infections, including those caused by methicillin-resistant S. aureus
Biofilms are clusters of microbes that almost always are found with healthcare-associated infections (HAIs) involving medical devices such as catheters, pacemakers and prosthetics. Most often biofilms that develop on such devices consist of Staph bacteria. Because biofilms inherently resist antibiotics and immune defenses, treating patients with biofilm-associated infections can be difficult and expensive. An estimated two million HAIs, most of which are associated with biofilms, occur in the United States annually, accounting for about 100,000
Although biofilm-related infections result in significant numbers of deaths, scientists still have a limited understanding of how biofilms develop at a molecular level. But now scientists from NIH’s National Institute of Allergy and Infectious Diseases (NIAID) have identified a specific S. epidermidis protein, called phenol-soluble modulin beta (PSM-beta), that biofilms use for multiple purposes: to grow, to detach from an implanted medical device, and to disseminate infection. Antibodies against PSM-beta slowed bacterial spread within the study mice, suggesting that interfering with biofilm development could provide a way to stop the spread of biofilm-associated
Similar proteins also are found in S. aureus, and the research group now plans to study their role in biofilms of MRSA and other
R Wang et al. Staphylococcus epidermidis surfactant peptides promote biofilm maturation and dissemination of biofilm-associated infection in mice. The Journal of Clinical Investigation 121(1): DOI: 10.1172/JCI42520 (2011).
Michael Otto, Ph.D., senior investigator, Laboratory of Human Bacterial Pathogenesis, NIAID. Dr. Otto is an expert in biofilms and Staphylococcus
NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at
The National Institutes of Health (NIH)—The Nation's Medical Research Agency—includes 27 Institutes and Centers and is a component of the U. S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments and cures for both common and rare diseases. For more information about NIH and its programs, visit